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1. Introduction 
Glioblastoma multiforme (GBM) is the most common primary brain tumors and remains 
one of the deadliest of human cancers [1]. The incidence of this cancer is fairly low, with 2-3 
cases per 100,000 people in Europe and North America. GBM is slightly more common in 
whites than in blacks, Latinos, and Asians, with a slight male predominance - M:F ratio of 
3:2 [2]. The overall prognosis for GBM has changed little in the past two decades, despite 
major improvements in neuroimaging, neurosurgery, radiation treatment techniques, 
adjuvant chemotherapy, and supportive care.  Without treatment, the median survival is 
approximately 3 months [3]. The current standard of care involves maximal surgical 
resection followed by concurrent radiation and chemotherapy with the DNA alkylating 
agent temozolomide [4]. Despite this aggressive regimen, the median survival remains 
approximately 14 months. Thus, meaningful strategies for therapeutic intervention are 
desperately needed. 
The most reliable evidence suggests that glioblastomas originate from cells that give rise to 
glial cells [5, 6]. The World Health Organization (WHO) classifies these glial-derived tumors 
into four major categories, namely WHO grade I-IV. The higher grade signifies patho-
histologic features of increased malignancy. WHO grade IV glioma is synonymous with 
glioblastoma [7].  
Rigorous scientific investigations over the past three decades indicate that glioblastomas, 
similar to other cancers, are the stem from collection of genetic alterations. These alterations 
can present in a variety of forms, including epigenetic alterations, point mutations, 
translocations, amplification or deletions – resulting in gene modifications. The genetic 
alteration results in either activation or inactivation of specific gene functions that may 
contribute to the process of carcinogenesis [8]. Those genes, that when activated, contribute 
to the development of cancer are often termed proto-oncogenes. The mutated forms of these 
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genes are referred to as oncogenes. Conversely, genes that when inactivated contribute to 
carcinogenesis are generally termed tumor suppressor genes. Although it is well established 
that central nervous system (CNS) carcinogenesis requires multiple deregulations of the 
normal cellular circuitry, the exact number and nature of genetic alterations and deregulated 
signaling pathways required for tumorigenesis remains subject of ongoing scientific 
investigations [9].  
1.1. Cancer genomic era 
The current decade will likely be remembered, in the history of cancer research, as the 
decade of cancer genomics. The marriage of technology and annotated specimen collection 
has culminated to provide us with a glimpse of the complex genomic landscape that 
underlies cancer pathogenesis. Remarkably, these efforts have demonstrated true 
collaborative spirits between clinicians and basic science researchers with common goals of 
furthering translational science. 
The Cancer Genome Atlas (TCGA) constitutes the largest of the genomic efforts. It is a 
comprehensive and coordinated effort to accelerate our understanding of the molecular 
basis of cancer through the application of genome analysis technologies, including large-
scale genome sequencing. This is accomplished via cataloguing the genetic and epigenetic 
changes in the cancer genome, with goals of identifying those responsible for 
carcinogenesis. The project represents a joint effort of the National Human Genome 
Research Institute (NHGRI), National Cancer Institute (NCI), the U.S. Department of Health 
and Human Services, and collects of tumor specimen from major cancer centers spanning 
across the continental USA. The project aims to provide the genomic profile of 500 
specimens of various cancer types using state-of-the-art platforms for sequencing, 
microRNA, mRNA, single- nucleotide polymorphisms (SNPs), and methylation profiling. 
TCGA started as a pilot project in 2006 with focus on glioblastoma as the first cancer type for 
study. With the success of the pilot project, TCGA has committed to expand its efforts to 
aggressively pursue 20 or more additional cancers. While acknowledging the importance of 
the TCGA in cancer research, one cannot neglect the value of the pioneering genomic efforts 
that, in many ways, laid the groundwork for the TCGA [10]. The knowledge to sequence the 
entire genomes of human tumors including glioblastoma, helps formulating new concepts 
and principles in tumor cell biology, and enables potential exploitation of these major 
advances for personalized disease management in oncology.  
With advances in genomic profiling and sequencing technology, we are beginning to 
understand the landscape of the genetic events that accumulate during the neoplastic 
process. The insights gleamed from these genomic profiling has been instrumental to 
advancing therapeutic strategy. This chapter will aim to review the existing data with 
regards to chromosomal aberration, mutations, non-doing sequences, over-expressed 
mRNA, miRNA dysregulation and will explore the opportunities for major therapeutic 
developments in the cancer gemonic era.  
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2. Chromosomal aberration 
Chromosomal aberration refers to an abnormality in the structure or number of 
chromosomal content of a cell. Increasingly, cancer is recognized as a heterogeneous 
collection of diseases whose initiation and progression are prompted by the aberrant 
function of genes that govern DNA repair, genome stability, cell proliferation, cell death, 
adhesion, invasion, angiogenesis in complex cell and tissue microenvironment [11, 12]. In 
addition to high-resolution chromosome banding and advanced chromosomal imaging 
technologies, chromosome aberrations in cancer cells can be analyzed with an increasing 
number of large-scale, comprehensive genomic and molecular genetic technologies. These 
growing technologies include fluorescence in situ hybridization (FISH) [13, 14], spectral 
karyotyping (SKY) [13], comparative genomic hybrizidation (CGH) [15, 16], and other high-
throughput methods that detects loss of heterzygosity (LOH) [17, 18], in cancer cells such as 
a new single nucleotide polymorphism arrays (SNP Chips) [19] that detect comprehensive 
genome-wide copy number changes. With the use of comprehensive molecular 
technologies, the discovery of the recurrent chromosomal aberrations in cancer is 
proceeding at a very promising pace. To date, glioblastoma has been subjected to the most 
extensive genomic profiling of any cancer [20]. Studies carried out over the past three 
decades suggest that glioblastomas, like other cancers, arise secondary to the accumulation 
of genetic alterations. These alterations can present as epigenetic modifications, point 
mutations, translocations, amplifications, or deletions, and modify gene function in ways 
that dysregulate cellular signaling pathways leading to the cancer phenotype [11, 21]. While 
the exact number and nature of genetic alterations and deregulated signaling pathways 
required for tumorigenesis remains an issue of debate, [9] it is now well understood that 
central nervous system (CNS) carcinogenesis requires multiple disruptions to the normal 
cellular circuitry [22, 23].  
Amongst chromosomal aberrations, amplifications and deletions can be distinguished when 
considering glioblastoma genesis [24]. Conversely, the reports of incidental translocation are 
rare in glioblastoma [25]. Thus we will mainly focus our review on chromosomal 
aberrations that present as amplification or deletion and discuss their contribution in the 
development of glioblastoma. 
2.1. Amplification 
Amplification of the epidermal growth factor receptor (EGFR) gene is a distinguishing 
feature in primary glioblastoma [26-28] Moreover, it is now evident that the type of genetic 
alterations involving EGFR in glioblastoma are distinct from those observed in other EGFR-
altered cancers, such as non-small-cell lung cancer (NSCLC). In glioma, focal EGFR 
amplification occurs at an extremely high level (>20 copies) [20]. Focal (limited to a few Mb) 
and broader (from several Mbs to entire chromosomes) copy number alterations (CNAs) 
that include the EGFR gene may have different molecular consequences [27]. Focal 
amplification of EGFR correlates with EGFR over-expression or mutations and deletions in 
the EGFR gene, and subsequent activation of the PI3K/AKT pathway [27, 29]. Up-regulated 
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PI3K/ AKT signaling has been associated with poor prognosis [30]. Evidence of 
RTK/RAS/PI3K activation has been reported in 88% of tumors, including contributions from 
unexpected mutations or deletions in NF1 (18%) and PIK3R1, which encodes the p85a 
regulatory subunit of PIK3CA [20].  
Furthermore, amplification of the entire chromosome 7 containing EGFR, MET [22] and its 
ligand HGF has been found to correlate with activation of the MET axis [20, 27].  EGFR 
amplification is reported to appear as double minutes (small fragments of extra-
chromosomal DNA), and extra copies of EGFR have also been found inserted into different 
loci on chromosome 7 [31].  Additionally ~50% of EGFR-amplified cells harbor the EGFRvIII 
mutant, which is an intragenic gene rearrangement generated by an in-frame deletion of 
exons 2–7 that encode part of the extracellular region [20]. Remarkably, gain of chromosome 
7 and amplification of EGFR have been found more frequently in short-term survivors [26, 
32], however to date EGFR alterations are not thought to be of prognostic importance in 
glioblastoma [28, 32, 33].  
Amplification of 12q13-15, where the oncogenes CDK4 and MDM2 are located, results in the 
disruption of both the retinoblastoma (RB) and p53 pathways [22, 27, 34, 35] Specifically, 
p53 signaling pathway has been reported to be impaired in 87% of the samples through 
CDKN2A deletion (49%), MDM2 (14%) and MDM4 (7%) amplification, and mutation and 
deletion of TP53 (35%) [20]. Pathway inactivating mutations in the RB pathway were 
described in glioblastomas prior to the large-scale genomic efforts [23, 36, 37] and the TCGA 
validated these results and demonstrated that mutations and gene amplifications disrupting 
RB function are found in approximately 68–80% of glioblastomas, signifying the critical 
importance of evading anti-growth signals [21]. RB signaling has been reported to be 
impaired in 78% of the samples through CDKN2 family deletion; amplification of CDK4 
(18%), CDK6 (1%), and CCND2 (2%); and mutation or deletion of RB1 (11%) [20]. 
Additionally, Genome-Wide Association Studies (GWAS) revealed that single nucleotide 
polymorphisms (SNPs) in the CDKN2A and CDKN2B have been identified as risk factors 
for glioma growth [21] [38, 39]. Moreover, the genes encoding the receptor tyrosine kinases 
KIT, KDR, and PDGFRA, adjacently located on chromosome 4q12, are frequently found to 
be (co)amplified [40].  Nearly 30% of human gliomas show expression patterns that are 
correlated with PDGFR signaling [41]. For instance, PDGFRA amplification is found in 15% 
of all tumors [30, 42]. Of those PDGFRA amplified tumors harboring gene amplification, 
40% harbor an intragenic deletion, termed PDGFRAD8, 9 [43], in which an in-frame deletion 
of 243 base pairs (bp) of exons 8 and 9 leads to a truncated extracellular domain [44]. Point 
mutations in PDGFRA are associated with amplification but, unlike EGFR, happen rarely. 
Elevated AKT phosphorylation has been observed in up to 85% of glioblastoma cell lines 
and patient samples [45]. RTK-independent activation of this pathway in glioblastoma can 
occur via mutation or amplification of PIK3CA (p110a) [46, 47], and PIK3CD (p110d) is also 
overexpressed in some gliomas [48]. Other amplified regions containing oncogenes, for 
example AKT3 [22, 49] and CCND2 [22, 27]. 
Over-expression of c-Myc is frequently observed in different tumor types, including 
glioblastoma, and usually results from chromosome translocation involving the c-Myc genes 
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in addition to gene amplification [50]. In a study it was reported that during multistep 
carcinogenesis using fibroblast lineages transfected with SV40 LT, expression levels of c-
Myc and Sp1 associate with the levels of telomerase activity in different stages of 
transformation [51]. Transcriptional regulation of hTERT is thought to be the chief 
mechanism of telomerase regulation. Cooperative action of c-Myc and Sp1 is required for 
full activation of hTERT promoter. Sp1 is also a key molecule that binds to GC-rich sites on 
the core promoter and activates hTERT transcription [51]. In the core promoter, multiple E-
boxes and Sp1 binding sites are located. C-Myc binds to these E-boxes through heterodimer 
formation with Max proteins and activates transcription of hTERT [52, 53]. This is a direct 
effect of c-myc that does not require de novo protein synthesis. Mad proteins are antagonists 
of c-Myc and switching from Myc/Max binding to Mad/Max binding decreases promoter 
activity of hTERT [51, 54-56]. Thus, up-regulation of these critical transcription factors may, 
at least in part, be involved in telomerase activation during carcinogenesis [57]. 
 
Amplified Region Gene of Interest References 
1q AKT3 [22, 49] 
3q PIK3CA [22, 23, 27] 
4q PDGFR [22, 34] 
7p EGFR, MET, HGF, CDK6 [22, 23, 27, 34, 35] 
8q c-MYC [50] 
12q CDK4, MDM2 [22, 27, 35] 
Table 1. Genes frequently identified to be amplified in glioblastoma 
2.2. Deletions 
Loss of heterozygosity LOH of chromosome 10q is the most common genomic alteration 
found in both primary and secondary glioblastomas [28, 35] and is associated with poor 
prognosis [26, 28]. Different regions are frequently lost at chromosome 10, including the 
regions containing PTEN, MGMT [28, 58], and ANXA7, an EGFR inhibitor [59]. PTEN 
directly antagonizes PI3K signaling and is one of the most frequently altered genes in 
cancer. It undergoes genomic loss, mutation, or epigenetic inactivation in 40%–50% of 
gliomas, resulting in high levels of PI3K activity and downstream signaling [60]. In addition, 
AKT activation due to PTEN loss likely contributes to RTK inhibitor insensitivity in 
glioblastoma [29, 61]. Another frequently deleted inhibitor of EGFR signaling is NFKBIA, 
which is located on chromosome 14; this deletion is also linked to poor survival [62]. 
Furthermore, loss of chromosome 9p, which contains a variety of tumor-suppressor genes, 
including CDKN2A, CDKN2B, and PTPRD, is frequently seen [28, 34, 63], especially in 
short-term survivors [26, 32]. CDKN2A and CDKN2B encode three important cell cycle 
proteins, p14ARF and p16INK4A, and p15INK4B [26-28, 34, 64], which are involved in the 
RB and P53 pathways. Deletion of CDKN2A and CDKN2B is often accompanied by deletion 
of CDKN2C on chromosome 1p32, which encodes another cell cycle protein p18INK4C [64]. 
LOH of chromosome 1p is found in both primary and secondary glioblastomas [65]. 
Longstanding hypothesis about the location of tumor suppressor gene at 1p has recently 
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been advanced by identification of the suggested candidate genes CIC and FUPB1 [66]. Co-
deletion of 1p and 19q is frequently seen in oligodendrogliomas and is, in those, associated 
with prolonged survival [32] and translocations [67]. Although this co-deletion has been 
observed in glioblastomas, no similar association has been identified elsewhere. Isolated 
LOH 19q is frequently observed in secondary glioblastoma [26, 65] and may be a marker of 
longer survival [26]. Moreover >50% of oligodendrogliomas has been reported to display 
loss of heterozygosity (LOH) at chromosomes 1p and 19q [68], although the targets of these 
deletions are still unclear. 
Frequent allelic losses on 22q indicating the presence of tumor suppressor genes have been 
found in primary and secondary glioblastomas [69]. LOH of 22q identified two sites of 
minimally deleted regions at 22q12.3–13.2 and 22q13.31 in primary glioblastomas and in 
most of the secondary glioblastomas. The affected shared deletion of 22q12.3 is the region in 
which the human tissue inhibitor of metalloproteinases-3 (TIMP-3) is located.  As its name 
implies, expression of TIMP-3 inhibits metalloprotease activity and impair glioblastoma 
migration and invasiveness [70]. Expectedly, deletion of TIMP-3 enhances glioblastoma 
invasiveness [69].  
It is important to note that the various deletions and amplifications do not exist in isolation. 
For instance, NFKBIA deletions and EGFR amplifications are essentially mutually exclusive 
events, suggesting that these events serve redundant functions in glioblastoma pathogenesis 
[62]. Systematic analysis of the patterns of co-occurrence of the various deletions and 
amplifications revealed genomic regions with synergistic tumor-promoting relationships 
[71]. Analysis of the general patterns of co-occurring and mutually exclusive regions in 
glioblastomas suggests common pathways that are disrupted during carcinogenesis. 
Targeting these pathways in the context of the genetic landscape of the glioblastoma 
constitutes one therapeutic strategy. 
 
Deleted Region Gene of Interest References 
9p CDKN2A, 2B [22, 27, 35] 
10q PTEN, MGMT, ANXA7 [22, 23, 34, 35] 
13q RB [22, 34] 
17p P53, NF1 [22, 23, 34] 
19q BAX [34, 65] 
22q TIMP3 [69] 
Table 2. Genes frequently identified to be deleted in glioblastoma 
3. Mutations  
The abnormal behaviors demonstrated by cancer cells are thought to be the result of a series 
of mutations in key regulatory genes. A detailed understanding of the genomic lesions 
underlying cancer will facilitate the identification of the cellular pathways and networks 
perturbed by genomic mutations, improve cancer diagnosis through molecular 
classification, enhance the selection of therapeutic targets for drug development, promote 
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the development of faster and more efficient clinical trials using agents targeted to specific 
genomic abnormalities, and create markers for early detection and prevention. Results from 
the genomic profiling efforts and a number of studies over the past three decades have 
revealed that nearly all glioblastomas harbor activating mutations in genes that play 
instrumental role in growth signaling cascades, evading apoptosis, insensitivity to 
antigrowth signals. In addition to amplifications and deletions, genes implicated in 
glioblastoma can be affected by somatic mutations. Point mutations include base 
substitutions, deletions, or insertions in coding regions and splice sites. Large-scale mutation 
analysis has identified mutations activating oncogenes and others inactivating tumor-
suppressor genes in glioblastoma.  
It was previously thought that glioblastoma arises from the acquisition of a defined set of 
mutations that occur in a particular temporal order. This model is largely grounded on the 
framework established in colon cancer, where a series of genetic alterations characterizes 
different phases of neoplastic progression [72]. This hypothesis is supported by the 
observation that Grade II astrocytomas typically harbor mutations in p53; Grade III 
astrocytomas harbor activating mutations/amplifications of CDKN2A (p16Ink4a); and 
Grade IV astrocytomas harbor mutations in PTEN and EGFR [73]. This data was interpreted 
to suggest that glioblastoma results from sequential inactivation of the p53, RB, and 
RTK/PI3K axes. While such a paradigm may hold true for a subset of the secondary 
glioblastomas, the picture emerging from the genomic characterization of primary 
glioblastomas reveals a much more dynamic process [22, 23]. The profile of somatic 
mutations in different glioblastomas is highly variable. These results suggest that most 
glioblastomas, primary or secondary, evolve along a multitude of pathways in response to 
differing selective pressures to achieve the phenotypes described by Hanahan and Weinberg 
[74]. 
Aberrant centrosome behavior, such as centrosome amplification, has been associated with 
mutation of TP53 and has been proposed as a primary source of genetic instability in human 
tumors. Mutations in ‘‘common’’ cancer genes, for example TP53 and PTEN, are very 
frequent in glioblastomas, but are not of prognostic importance [22, 23, 28, 32, 33, 75]. On the 
other hand PTEN loss has been shown clinically to confer resistance to EGFR inhibitors in 
patients harboring EGFRvIII expressing glioblastoma in part due to its activation of 
downstream AKT [29, 76] as well as loss of its RTK degradation function [76]. 
There are several lines of evidence that point to the importance of the p53 axis in 
glioblastoma pathogenesis. There is a body of literature associating p53 pathway 
inactivation to glioblastoma genesis [37, 77]. It must be noted that these studies implicate 
p53 pathway inactivation only in a subset of glioblastomas. The TCGA effort and the effort 
by Parsons et al. [22, 23] enhanced the literature by demonstrating that the p53 axis is more 
broadly impaired in glioblastomas than previously thought. Mutations that inactivate this 
axis are found in greater than 70% of all glioblastoma specimens as reported by both studies. 
This understanding has led to more accurate modeling of glioblastoma by combined 
inactivation of p53 and PTEN [78]. 
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There are a number of mutations that are thought be glioblastoma specific, even though they 
may be seen in only a subgroup of tumor cells. The EGFRvIII mutant lacks 267 amino acids 
in the extracellular part, resulting in a constitutively activated receptor that no longer 
requires its ligand EGF to signal downstream [79]. Despite the well-recognized 
proproliferative functions of EGFRvIII, its expression in human glioblastoma is 
heterogeneous and is most often observed only in a subpopulation of cells [80]. Recent 
observations support a model of functional heterogeneity in which a minority of EGFRvIII-
expressing cells not only drive their own intrinsic growth, but also potentiate the 
proliferation of adjacent wild-type EGFR-expressing cells in a paracrine fashion through the 
cytokine co-receptor gp130 [81]. EGFRvIII expression may be linked to differentiation and/ 
or development. EGFR point mutations have also been identified in glioblastoma, in the 
extracellular domain, whereas they are predominantly found in the kinase domain in other 
tumor types, such as lung cancer [82]. EGFR mutations have recently been identified as 
clinically significant, due to their association with striking responses in subsets of patients 
treated with targeted therapeutic agents. [83, 84].  
The PI3K signaling pathway is dysregulated in many cancers [85], including glioblastomas. 
A number of investigations have reported activating mutations in the RTK–PI3K pathway 
[43, 86], validating the importance of this pathway in glioblastoma pathogenesis. Mutations 
in PIK3CA and PIK3R1, coding for the PI3K catalytic subunit p110a and regulatory subunit 
P85a, have been described [22, 23]. RTK-independent activation of this pathway in 
glioblastoma can occur via mutation of PIK3CA (p110a) [46, 47] or through recurrent 
mutations in the gene encoding the p85a regulatory subunit PIK3R1. This will likely drive 
PIK3CA activation through decreased SH2 domain-mediated inhibition [87]. In the TCGA 
report [22] activating mutations in the RTK–PI3K pathways are reported in 88% of the 206 
glioblastomas sequenced.  
Although mutations in the RAS genes constitute a fairly rare phenomenon in glioblastoma 
(>5%) [88], inactivating mutations and deletions have been identified in their inhibitory 
tumor suppressor gene NF1 [22]. The protein encoded by neurofibromatosis 1 (NF1) 
functions to catalyze the exchange of GTP for GDP in Ras - preventing cell proliferation. 
While it is reported that NF1 patients are predisposed to gliomagenesis [89], inactivating 
mutations in NF1 was not discovered in glioblastoma until recently [22, 23, 90, 91]. The 
TCGA results indicated that approximately 20% of glioblastomas harbor loss of function 
mutations in NF1 [22, 23] and more significantly, mutations in NF1 appear to define a 
particular subtype of glioblastoma.  
The majority of malignant brain tumors, including glioblastoma, demonstrate inactivating 
mutations in either the p53 and/or retinoblastoma (RB) pathways [92-95]. In addition to their 
adverse cellular functions, these two pathways are most directly involved in cell cycling 
regulations during times of cell repair or cell growth.  
The TP53 tumor suppressor gene, located on 17p13, is frequently mutated or deleted in 
gliomas [96, 97]. P53 is a short-lived transcription factor that can execute diverse cellular 
programs, such as cell cycle arrest, DNA repair, apoptosis, autophagy, differentiation, 
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senescence and self- renewal [98, 99]. It facilitates DNA repair by halting the cell cycle for 
repair enzymes to work, or if the damage is too great, it induces cell death. The 
retinoblastoma (Rb, 13q14) pathway is also a key cell cycle regulatory complex at the G1 
checkpoint. CDKN2A, located on 9p21 and deleted in many cancers, encodes the p16 
protein, a key inhibitor of the cell cycle via Rb pathway signaling. Homozygous deletion of 
p16 has been reported to be associated with WHO grade III or IV gliomas [7, 100]. Gliomas 
often display mutations in the ARF- MDM2-p53 and p16INK4A-CDK4-RB tumor 
suppressor pathways [101, 102]. Primary glioblastoma often exhibits loss of the INK4A/ARF 
tumor suppressor gene locus along with PTEN mutation and EGFR amplification/mutation, 
and secondary glioblastoma shows frequent mutations of TP53 [58].  
The relevance of p53 to the treatment and outcome of patients with high-grade glioma has 
remained controversial. Some studies have shown that p53 status, assayed either by 
expression or mutation analysis, is correlated with relatively good outcome [103, 104], while 
others have demonstrated no prognostic impact in anaplastic gliomas and GBM [105, 106]. 
Also, MDM2 amplification, although infrequent, has been shown by some to be predictive 
of poor outcome [103, 107], whereas others have observed no prognostic value [108]. P53 
status might cooperate with other prognostic variables; for example, TP53 mutation has 
been linked to low MGMT mRNA expression [109], although this does not correlate with 
MGMT promoter methylation [110]. Loss of CDKN2A, CDKN2B, or RB or CDK4 
amplification, disrupting the Rb pathway, has been shown in anaplastic astrocytoma to 
associate with decreased survival [111, 112]. Conversely, p16 appears to be associated with 
improved survival in patients treated with chemotherapy and radiation [113]. Overall, it 
appears that the prognostic impact of p53 and Rb aberrations is at best marginal.  
Comprehensive analysis of genomic data in glioblastoma revealed recurrent mutations in 
the R132 residue of isocitrate dehydrogenase 1 (IDH1) and is involved in energy metabolism 
[23]. IDH1/2 is mutated in grade II and III gliomas as well as the secondary glioblastomas 
that arise from prior low-grade tumors, with most mutations found in the IDH1 gene. IDH1 
mutations have been predominantly identified in secondary glioblastomas and low-grade 
gliomas, with mutations in more than 70% of cases [23, 114-118]. Patients with IDH1 
mutated primary glioblastomas are generally younger and have longer median survival and 
wild-type EGFR. Because these are characteristics of secondary glioblastomas, it is 
hypothesized that these are in fact secondary glioblastomas for which no histological 
evidence of evolution from a less malignant glioma is found. Significantly, these mutations 
usually occur at conserved residues and are virtually never homozygous. While only 3%–7% 
of primary glioblastomas harbor IDH1 mutations, the majority (50%–80%) of secondary 
glioblastomas express mutant IDH1. Thus, IDH1 could be used to differentiate primary 
from secondary glioblastomas [116]. In addition, 3% of the tumors that express wild-type 
IDH1 were found to express IDH2 R172 mutations [117-120], although this mutation in 
IDH2 has only been documented in a single glioblastoma in the literature [121].  
Studies on the downstream biological effects of IDH1/2 mutation expression have focused 
largely on the inhibition of α-KG-dependent dioxygenases by 2-HG, as IDH mutations 
result in a novel function to catalyze α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG) 
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[122]. The wild-type IDH1 normally functions as a homodimer that converts isocitrate to α-
ketoglutarate [120]. Biochemical depiction of the R132 mutated IDH1 revealed that it functions 
to inhibit the process. Thus, glioblastoma harboring the R132 IDH1 mutation harbor decreased 
levels of α-KG. It is imperative to note that α-KG dependent dioxygenases is a diverse group 
of enzymes controls a broad range of physiological processes, including hypoxic sensing, 
histone demethylation, demethylation of hypermethylated DNA, fatty acid metabolism, and 
collagen modification, among others [123]. Several studies have provided evidence to 
demonstrate that several of these functions are influenced by IDH1/2 mutation expression.  
Mutational and epigenetic profiling of patients specimen has revealed that IDH1 mutations 
closely associated with a specific hyper-methylation signature. The hyper-methylation state 
may be caused in part by the 2-HG-mediated inhibition of the α-KG-dependent TET2 
enzyme [124, 125]; the resultant decrease in 5-hydroxymethylcytosine was also observed in 
glioblastoma specimens [124]. Moreover, expression of IDH1 mutations is thought to induce 
global DNA hyper-methylation [126]. Thus it is suggested that IDH1 mutations may lead to 
dysregulated epigenetic processes. 2-HG inhibits histone demethylases and TET 5-
methylcytosine hydroxylases, thought to be involved in epigenetic control. This suggests 
that mutations in IDH1 change the expression of a potentially large number of genes [124].   
Most lower-grade gliomas harbor IDH1 mutations; although grade I pilocytic astrocytomas 
usually express wild-type IDH1; 60%–80% of grade II and III astrocytomas, 
oligodendrogliomas, and oligoastrocytomas express mutant IDH1, with the R132H mutation 
representing the majority of mutations observed. Given that mutations in IDH1 are an early 
event in gliomagenesis [127], this may suggest widespread modification of epigenetic 
regulator as the key mechanism in gliomagenesis in IDH1 mutated tumors. Furthermore, it 
might explain the extensive and fundamental differences between mutated and wild-type 
IDH1 glioblastoma. It has been reported that global expression profiles of IDH1 mutant 
glioblastomas more closely resembled lineage-committed neural precursors, whereas wild-
type counterparts appear to resemble neural stem cells [128].  
Independent glioblastoma studies have pointed to IDH1 mutations as an objective positive 
prognostic marker [23, 114, 115, 120]. Reports of the association between IDH1 mutations 
and favorable prognosis hold promise for biomarker development [23, 42, 120], although 
these correlations await validation in prospective clinical trials. Thorough understanding of 
mutant IDH biology and the mutant status of the IDH1/2 genes may serve as a key 
prognostic indicator. Specifically, patients with anaplastic astrocytoma [23, 115, 120, 121] 
and glioblastoma harboring mutant IDH1 demonstrate a significantly longer overall 
survival compared with wild-type IDH1 counterparts and are younger at presentation. 
Similar survival benefit has also been observed in grade II gliomas. [115] Furthermore, a 
comprehensive genomic and clinical analysis of glioblastomas harboring mutant and wild-
type IDH1 suggests that, while histo-pathologically similar, these tumors may represent 
disease processes far more unique than has been appreciated. Specifically, IDH1 mutant 
tumors display less contrast enhancement, less peritumoral edema, larger initial size, greater 
cystic components, and a greater likelihood of frontal lobe involvement compared with 
wild-type tumors [128]. 
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A frequently encountered critique of genomic sequencing effort involves the following. The 
first generation sequencing used to characterize the glioblastoma landscape captures the 
most prevalent mutations. They did not analyze the deeper heterogeneity of low prevalence 
mutations that have been found in several tumor types, including colon cancer [129]. Efforts 
to examine whether such sub-clonal diversity exist in glioblastoms using highly sensitive 
techniques [130] have not identified the presence of low-prevalence mutations. These results 
suggest that clonal expansion of select mutation in glioblastoma constitute a major 
mechanism of tumor expansion and that random mutagenesis through mutator phenotype 
does not contribute significantly to glioblastoma pathogenesis. The insights gained from the 
TCGA and other sequencing efforts should be viewed in this light.  
4. Non-coding DNA sequences 
While the identification of nucleotide alterations within the coding sequence of 
protooncogenes or tumor suppressor genes has significantly contributed to our 
understanding of carcinogenesis, there is an emerging appreciation that alterations in non-
coding sequences similarly contribute to development of cancer [131]. Non-coding DNA 
describes components of DNA arrangements that do not participate in the coding of protein 
sequences. These DNA sequences may present in different forms including non-coding 
functional RNA, cis- and trans-regulatory elements, introns, pseudogenes, repeat sequences, 
transposons, and telomeres. A notable example involves the regulation of gene transcription 
by reversible modification of gene promoter regions a phenomenon often referred to as 
‘epigenetic regulation’ [132]. The term ‘epigenetic regulation’ describes the phenomenon in 
which heritable changes in gene expression can occur in the absence of changes in the DNA 
sequences encoding for gene function. Understanding the concept that non-coding 
sequences play critical roles in glioblastoma pathogenesis and resistance to chemotherapy 
offers novel strategies for biomarker development and therapy.  
The mechanism underlying epigenetic involves cytosine methylation [133] or histone 
modifications that, in turn, modulate the accessibility of gene promoter regions to 
transcriptional factors [134]. Cytosine methylation often occurs in the context of CpG di-
nucleotide repeats, or CpG islands [133]. Thus promoters that harbor heavily methylated 
CpG islands are typically transcriptionally silenced. There are two types of promoter 
methylation that are particularly pertinent to glioblastoma therapy: methylation in the 
promoter region of the DNA repair gene, methyl-guanine methyl transferase (MGMT) and 
the glioma-CpG island methylator (G-CIMP) phenotype [135]. 
MGMT encodes an enzyme that removes alkyl adducts at the O6 position of guanine [136]. 
Because alkyl modification at this position is highly toxic and constitutes the primary 
mechanism for the tumoricidal activity of the chemotherapeutic agent TMZ, MGMT 
expression level correlates well with TMZ response in patients with glioblastoma [137]. The 
human MGMT gene possesses a CpG island that spans approximately 1000 bases around 
the transcriptional start site. Detailed analysis of this region revealed 108 CpG sites [138] 
that are methylated. Methylation of a subset of these CpGs has been associated with 
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transcriptional silencing of MGMT [139, 140]
 
and is associated with improved clinical 
outcome in patients with glioblastoma receiving TMZ therapy. Interestingly, MGMT 
promoter methylation is also associated with improved survival in patients who did not 
receive TMZ therapy [141, 142]. While the mechanism underlying this observation remains 
unclear, it seems likely that MGMT may participate in detoxifying the accumulation of 
endogenous DNA damage that is typically associated with the oncogenic state [143]. 
Glioblastoma cells accumulate endogenous DNA damage in the absence of DNA damaging 
agents [143]. These endogenous DNA damages are not unlike those induce by 
temozolomide or radiation in that they could trigger cell death if unrepaired. Thus, tumors 
with high levels of MGMT may grow more robustly since MGMT is capable of detoxifying 
these endogenous DNA damages. If the tumor cells grow more robustly, the patient will 
survive for a shorter duration. In contrast, the glioblastoma cells with low MGMT may be 
more susceptible to the deleterious effects of the endogenous DNA damages. These tumors 
may grow less robustly, resulting in longer patient survival. 
The G-CIMP phenotype refers to the observation that a subset of glioblastomas exhibits 
concerted CpG island methylation at a large number of loci [144]. Since genes required for 
tumour growth are located at many of these loci, glioblastomas harboring the G-CIMP 
phenotype tend to be more benign. Correspondingly, patients with G-CIMP glioblastomas 
experienced significantly improved outcome. Understanding the concept that the patterns of 
CpG island methylation directly impact outcomes in patients with glioblastoma open the 
door to therapeutic strategies aimed at enhancing promoter methylation at select promoter 
loci. Importantly, recent studies suggest that promoter methylation at distinct loci may be 
affected by specific chromatin-modulating factors [135, 145]. 
While much of cellular DNA has no known biological function, many types of non-coding 
DNA sequences do have recognized biological functions, including the transcriptional and 
translational regulation of protein-coding sequences. These governing functions may 
include genetic switches, regulation of gene expression, transcription factors, operators, 
enhancers, promoters, and insulators [146-148]. Genome-wide association (GWA’s) studies 
have uncovered a large number of cancer susceptibility regions that do not overlap protein-
coding genes but rather map to non-coding intervals [132, 135]. The concept that non-coding 
DNA sequences regulate gene function and impact carcinogenesis has significantly 
expanded the repertoire of strategies available for glioblastoma therapeutics [135]. 
Integrating the biology of non-coding sequences in the context of mutational profile is 
critical in understanding tumor physiology and meaningful therapeutic development. 
5. Over-expressed mRNA 
Over-expression or under-expression of genes in glioblastoma compared with that in a 
normal brain or in low-grade gliomas may serve as an indication of genes that are involved 
in gliomagenesis [24]. While glioblastoma has been conceptualized as a single disease, it is 
widely appreciated that the term captures significant histologic heterogeneity. This 
heterogeneity suggests distinct subtypes with differing physiologic states that are captured 
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under the umbrella term ‘‘glioblastoma’’ [21]. In fact, the genome-wide analysis of mRNA 
expression to identify molecular subclasses (Golub et al. 1999) has led to a fundamental shift 
in our understanding of glioblastoma subtypes. In fact, the identification of multiple 
subtypes within glioblastoma has highlighted the heterogeneity of diseases that are in the 
same group based on the WHO histo-pathological grade.  
Primary and secondary glioblastoma subtypes are histo-pathologically indistinguishable, 
but differences can be demonstrated by molecular markers at the epigenetic [69], genetic [28, 
35, 58], expression [149], and proteomic [150] levels. Primary glioblastomas have a greater 
prevalence of EGFR alterations, MDM2 duplications, PTEN mutations, and homozygous 
deletions of CDKN2A [28, 58]. MET amplification [35], over-expression of PDGFRA, and 
mutations in IDH1 and TP53 are more prevalent in secondary glioblastomas [23, 29, 58, 75, 
114, 116, 118]. Moreover, the large-scale analysis has revealed the highly structured nature 
of glioma transcriptome and has shown correlation of tumor histology and molecular 
alterations with patient outcome [10, 24, 42]. While expression profiling of glioblastoma has 
been widely used, two fundamental studies have provided the groundwork for the 
classification of glioblastoma subtypes [30, 42]. The first subtype initially reported by 
Phillips et al. [30] and subsequently confirmed by the TCGA mRNA [42] and microRNA 
profiling [151]. The transcript signature resembles those of neuro-blasts and 
oligodendrocytes derived from fetal and adult brain cells [30]. The subtype harbors 
transcriptomal and clinical features that emulate those previously classified as secondary 
glioblastomas. Molecularly, proneural glioblastomas harbor mutations classically associated 
with the secondary glioblastomas [42]. Hence, grade II and III gliomas harbor 
transcriptomal signatures most reminiscent of the proneural subtype [30]. Clinically, this 
subtype typically affects younger patients, is associated with improved overall survival [30], 
and responds poorly to concurrent radiation/temozolomide treatment upon disease 
progression [42]. 
The second subtype that has emerged is characterized by a gene expression signature that 
illustrates those observed in the neural stem cells of the forebrain [30], cultured astroglial 
cells [152], and tissue of mesenchymal origin [30]. Thus, the subtype is termed 
‘‘mesenchymal’’ for the latter correlation. Similar to the proneural subtype, this second 
subtype was initially identified by Phillips et al. [30] and subsequently confirmed by the 
TCGA [42]. This subtype is highly enriched for mutations inactivating NF1, suggesting a 
common genetic etiology. The mesenchymal signature appear driven a common 
transcriptional network, as expression of two key critical factors (STAT3 and CEBPb) 
enhance tumor aggressiveness in murine models [153].  
Benefiting from unsupervised hierarchical clustering analysis, Verhaak et al. (2010) 
classified 200 TCGA glioblastoma samples into four subtypes, which were subsequently 
validated using previously published data from 260 independent samples. Large-scale 
expression studies are validated by reverse transcription (RT)-PCR for individual genes. 
Bioinformatics analysis revealed that three of the four subtypes were found to harbor 
distinct molecular aberrations. In particular, the proneural subtype was enriched for 
amplifications of PDGFRA, CDK6, CDK4, and MET; 11 out of 12 IDH1 mutations found in 
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the TCGA samples; PIK3CA/ PIK3R1mutations; and mutation or LOH of TP53. While the 
mesenchymal subtype carries mutations and/or loss of NF1, TP53, and CDKN2A, the 
classical subtype shows amplification for EGFR and loss of PTEN. On the other hand, to 
date no distinguishing genetic alterations have been indicated to define the neural class 
from the other classes [20]. It is imperative to keep in mind that interpretations of these 
results are difficult due to methodological differences in profiling platforms, bioinformatic 
extrapolation, and specimen collection.  
While the number of subtypes identified by the Verhaak et al. (2010) and Phillips et al. 
(2006) studies differs, the proneural and mesenchymal classifications identified using 
distinct methodologies and sample sets are the most robust and concordant [10]. For 
instance, both groups identified proneural class expression of DLL3 and OLIG2 and 
mesenchymal class expression of CD40 and CHI3L1/YKL-40, the latter of which appears to 
be a potential serum protein marker of prognosis in glioblastoma patients [154]. Both studies 
share the observation that patients afflicted with the mesenchymal subtype exhibit poorer 
clinical prognosis relative to the proneural subtype. A high level of expression of insulin-like 
growth factor binding proteins, for example IGFBP-2/3 [155], angiogenesic factors, such as 
vascular endothelial growth factor A (VEGFA) [156], and mesenchymal markers, like YKL-
40/CHI3L1, are frequently seen in glioblastoma and have been associated with poor 
prognosis [157-159]. In contrast, NOTCH signaling genes, for example DLL3, are indicative 
of better survival [160]. 
Hence, the collection of data suggests at least two distinct subtypes that reflect essential 
biologic behavior [10, 30, 42] and have been validated by independent studies. In addition to 
promising improvement in the grading of glioblastoma, gene expression profiling has 
shown great promise in prognosis of this deadly tumor, as the genes represented in these 
subtypes could help to predict outcome in glioblastoma. For example, increased expression 
of mesenchymal genes such as CHI3L1/YKL-40 and LGALS3 combined with decreased 
expression of a proneural gene, OLIG2, are associated with typical short-termsurvival 
compared with longer-termsurvivors [161]. Additional studies have extended the utility of 
mRNA profiling by using computational network analysis to uncover the causal regulatory 
modules underlying particular transcriptomically defined subtypes. It is important to note 
that most of these subtypes have not been as rigorously validated as the proneural and the 
mesenchymal. The emerging literature suggests that the proneural and mesenchymal 
subtypes define the two poles in the spectrum of molecular glioblastoma physiology [10, 30, 
42]. It remains unclear whether the other proposed subtypes constitute a ‘‘forced fit’’ of a set 
of truly heterogeneous biology, a gradation of phenotypes between the two extreme poles, 
or a genuine subtype whose biologic basis remains to be understood.  
With genomics approaches, discoveries of common features of different types of tumor may 
lead to new therapeutic targets and drugs for other tumor types also. The discovery of 
overexpression of VEGFA and its correlation with poor prognosis in glioblastomas [156] led 
to trials with the angiogenesis inhibitor bevacizumab.  
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6. Micro-RNA (miRNA) dysregulation 
Micro-RNAs (miRNA or miR) are a class of small non-coding RNAs, approximately 22 
nucleotides long that are involved in post-transcriptional gene regulation [162]. Through 
imperfect pairing, miRNA’s bind to untranslated regions of protein-coding mRNAs and 
function mainly as negative regulators of gene expression. Binding of miRNA often leads to 
mRNA degredation or inhibition of protein translation – resulting in suppression of the 
target proteins. A number of cellular processes are regulated by miRNAs including 
development, proliferation, and differentiation. Micro-RNAs play an important role in 
many different disorders, particularly in cancer [163]. Bioinformatic analysis predicts that a 
single miRNA can potentially regulate hundreds of target oncogenes or tumour suppressor 
proteins. The association of miRNA deregulation with pathogenesis and progression of 
malignant disease illustrates great potential of utilizing miRNAs as targets for therapeutic 
intervention. Thus, modulation of miRNA expression provides great hope for potential 
cancer therapy. Furthermore, since each miRNA may have more than one target, miRNA-
based gene therapy offers the therapeutic appeal of targeting multiple gene networks that 
are controlled by a single miRNA [164]. Over 1000 miRNAs have been described in humans 
[165]. Bioinformatics analysis has recently revealed that miRNAs are differentially 
expressed in glioblastoma tissues compared to normal brain tissue [166-169]. For example, 
while primary glioblastomas and cell lines over-express miR-221 and miR-222, which are 
thought to target cell cyclin-dependent kinase inhibitors p27 and p57, set of brain-enriched 
miRNAs (miR-128, miR-181a, miR-181b, and miR-181c) show reduced expression [170, 171].  
 
Figure 1. Gene regulation by non-coding RNAs. Figure is adapted with permission from reference 
[135].  
Frequently up-regulated miRNAs are called onco-miRNAs and are thought to contribute to 
carcinogenesis. As an example miRNA-10b is known to be highly expressed in glioblastoma 
samples [170], suggesting an important role for miR-10b in glioblastoma tumorigenesis. 
Furthermore, a recent study revealed that miR-10b expression is inversely correlated with 
glioblastoma patient survival [172]. Notably, miR-10b was also found to be up-regulated in 
breast cancer, leukemia, and pancreatic cancer and promote tumor invasion and metastasis 
in breast cancer [173-175]. These results suggest that some miRNAs, such as miR-10b, may 
function as a global oncogene to trigger tumorigenesis in multiple tissues. Another example 
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of onco-miRNA in glioblastoma is miR-26a, which is thought to target PTEN [176]. PTEN 
has been reported to be down-regulated in 70% of human cancers, and there are several 
indications that it functions as a haplo-insufficient tumor suppressor gene [177]. PTEN 
expression is down-regulated by several different miRNAs, and it is thought that post-
transcriptional regulation is an essential player in determining PTEN abundance in cancer 
cells. By targeting the tumor suppressor PTEN, overexpression of miR-26a facilitates 
tumorigenesis [168, 176]. Furthermore, miR-26 cooperates with oncogenes CDK4 and 
CENTG1, forming an onco-miRNA/oncogene cluster, targeting the RB, PI3K/AKT, and JNK 
pathways and increasing aggressiveness in glioblastoma [168]. Over-expressed oncogenic 
miRNAs may be targeted by antagomirs or miRNA sponges, because over-expression of the 
onco-miRNAs miR-26a, miR-196, and miR-451 has been correlated with poorer survival 
[167].  
In contrast with the onco-miRNA’s, frequently down-regulated miRNA’s in glioblastoma 
are considered tumor-suppressor miRNA’s. Reduced miR-128 expression in glioblastoma 
and consequent reduced cell proliferation in vitro and in xenografts [178]. Furthermore, miR-
128 regulates the expression of the complex protein Bmi-1 through binding at the BMI-1 3′-
UTR, resulting in decreased Bmi-1 and H3K27me3 levels. In GBM-derived neurosphere 
cells, miR-128 over-expression has been reported to block stem cell self-renewal, indicating 
that miR-128 can govern the stem cell-like capabilities of a subset of GBM cells [132]. 
Glioblastoma tumor tissue profiling has revealed that miRNA-124 is down-regulated in 
glioblastoma tissue [163, 170].  Notably, miR-124 is also frequently down-regulated in other 
cancers, such as medulloblastoma, hepatocellular carcinoma, and oral squamous carcinoma 
[179, 180], suggesting that it may function as a general tumor suppressor. Moreover, 
miRNA-137 and miRNA-451 exhibit reduced expression in malignant glioblastoma tissues 
relative to normal brain tissues [181, 182].  
Despite advances in biomedical science, the prognosis of glioblastoma patients remains 
poor. Biomarkers for this disease are needed for early detection of tumor progression. 
Clinical significance of miRNA expression profiles in glioblastoma has not been explored 
extensively. Nevertheless, 16 candidate miRNAs have been described to associate with 
malignant behavior of gliomas (miR-196a, miR-15b, miR-105, miR-367, miR-184, miR-196b, 
miR-363, miR-504, miR-302b, miR-128b, miR-601, miR-21, miR-517c, miR-302d, miR-383, 
miR-135b). Among them, miR-196a and miR-196b indicated the highest level of significance) 
[183]. Both miRNAs showed increased expression levels in glioblastomas relative to 
anaplastic astrocytomas and normal brain tissues. Higher level of miR-196 transcript 
significantly correlated with poorer survival [167, 183]. Treatment of malignant gliomas 
remains one of the greatest challenges facing oncologists today through a frequent 
resistance to both chemo- and radiotherapeutic agents [184]. Important question for 
management of glioblastoma patients is the possibility of predicting therapeutic outcome. 
The miRNA expression profiles of glioblastoma tissues have shown association of miR-181b 
and miR-181c with response to concomitant chemoradiotherapy with temozolomide 
(RT/RMZ). MiR-181b and miR-181c were significantly down-regulated in glioblastoma 
tissue of patients who responded to RT/TMZ in comparison to patients with progressive 
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disease [183, 185]. In a recent study by Zhang et al. [186] genome-wide miRNA profiling of 
82 glioblastomas demonstrated that miR-181d was inversely associated with patient overall 
survival and temozolomide (TMZ) treatment. Bioinformatics analysis of potential genes 
regulated by miR-181d revealed methyl-guanine-methyl-transferase (MGMT) as a 
downstream target. Together, these results suggest that miR-181d is a predictive biomarker 
for TMZ response and that its role is mediated, in part, by post-transcriptional regulation of 
MGMT. 
The basic strategy of current miRNA-based treatment studies is either to antagonize the 
expression of target miRNAs with antisense technology or to restore or strengthen the 
function of given miRNAs to inhibit the expression of certain protein-coding gene.  
Unfortunately, several major challenges have to be addressed before the application of 
miRNA-based treatment. First, the multi-targeting nature of miRNAs gives the risk of 
unintended off-target effects that need to be carefully evaluated. Moreover, the expression 
of target gene may be governed by several different miRNAs, which may compromise the 
effect of miRNA-based treatment. Finally, there is still lack of miRNA delivery system with 
enough specificity and efficacy [183].  
 
 
Figure 2. TCGA revealed genes that are known to contribute to the cancer phenotype, as proposed by 
Hanahan and Weinberg (2011). Figure is adapted with permission from reference [8].  
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7. Conclusion 
In this chapter, we have reviewed and discussed key molecular participants glioblastoma, 
including chromosomal aberration, mutations, non-coding DNA sequences, over-expressed 
mRNA, and miRNA dysregulation. We placed our focus to explore the opportunities for 
major therapeutic developments in the cancer genomic era, where a more comprehensive 
mechanistic insight into glioblastoma pathogenesis and biology is arguably the most 
promising approach to discoveries of innovative treatment strategies. 
Future development of tools for subtyping, biomarker development, and therapeutic 
strategies grounded in the genomic landscape of the particular glioblastoma will facilitate 
clinical trial designs. Ultimately, robust therapeutic gain can be achieved only when agents 
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